These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1580272)

  • 21. A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology.
    Kemper P; Köhler D
    Am J Med; 1992 Apr; 92(4A):98S-102S. PubMed ID: 1316079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
    Gotfried MH; Ellison WT
    Am J Med; 1992 Apr; 92(4A):108S-113S. PubMed ID: 1316059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of quinolones in the treatment of lower respiratory tract infections caused by intracellular organisms, excluding mycobacteria].
    Chidiac C; Senneville E; Mouton Y
    Pathol Biol (Paris); 1992 Jun; 40(6):638-45. PubMed ID: 1408383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections.
    Kosmidis J
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():73-9. PubMed ID: 1664832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fluoroquinolones: pharmacology, antibacterial spectrum and indications in pneumology].
    Underner M; Grignon B; Roblot F; Meurice JC; Patte F
    Rev Pneumol Clin; 1989; 45(1):14-22. PubMed ID: 2662344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of fluoroquinolones in respiratory tract infections.
    Grossman RF
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():59-62. PubMed ID: 9484874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of temafloxacin in the community setting: an overview.
    Ball P
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():121-30. PubMed ID: 1664825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Causative role of infections with viruses or atypical pathogens in acute exacerbations of chronic bronchitis less frequent than expected].
    Roessingh PH; van Loon AM; Lammers JW; Hoepelman IM
    Ned Tijdschr Geneeskd; 1996 Nov; 140(48):2406-10. PubMed ID: 8984413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penetration of lomefloxacin into bronchial secretions following single and multiple oral administration.
    Bergogne-Bérézin E; Muller-Serieys C; Kafé H
    Am J Med; 1992 Apr; 92(4A):8S-11S. PubMed ID: 1316076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profile of sparfloxacin in the treatment of respiratory tract infections.
    Rubinstein E
    J Antimicrob Chemother; 1996 May; 37 Suppl A():145-60. PubMed ID: 8737134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Wadworth AN; Goa KL
    Drugs; 1991 Dec; 42(6):1018-60. PubMed ID: 1724637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enterobacter pneumonia.
    Karnad A; Alvarez S; Berk SL
    South Med J; 1987 May; 80(5):601-4. PubMed ID: 3576272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower respiratory tract infections and community acquired pneumonia in adults.
    Stocks N; Turnidge J; Crockett A
    Aust Fam Physician; 2004 May; 33(5):297-301. PubMed ID: 15227857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.